Ardelyx Inc - ESG Rating & Company Profile powered by AI
This analysis of Ardelyx Inc uses data points from across the internet and also from public documents by Ardelyx Inc. This ESG rating covers seventeen UN SDGs including: 'Clean Water & Sanitation', 'Sustainable Cities & Communities' and 'Partnerships for the Goals'. Comprehensive ESG analysis of Ardelyx Inc can be accessed by registering for free.
Ardelyx Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.4; made up of an environmental score of 2.7, social score of 1.6 and governance score of 6.0.
3.4
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1186 | Simply Better Brands Corp | 3.5 | Medium |
| 1186 | Yunnan Baiyao Group Co Ltd | 3.5 | Medium |
| 1234 | Ardelyx Inc | 3.4 | Medium |
| 1234 | Cassava Sciences Inc | 3.4 | Medium |
| 1234 | Brickell Biotech Inc | 3.4 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Ardelyx Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Ardelyx Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Ardelyx Inc report the average age of the workforce?
Sign up for free to unlockDoes Ardelyx Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Ardelyx Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Ardelyx Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Ardelyx Inc offer flexible work?
Sign up for free to unlockDoes Ardelyx Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Ardelyx Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Ardelyx Inc conduct supply chain audits?
Sign up for free to unlockDoes Ardelyx Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Ardelyx Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Ardelyx Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Ardelyx Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Ardelyx Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Ardelyx Inc disclose water use targets?
Sign up for free to unlockDoes Ardelyx Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Ardelyx Inc have a product recall in the last two years?
Sign up for free to unlockDoes Ardelyx Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Ardelyx Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Ardelyx Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Ardelyx Inc disclose parental leave metrics?
Sign up for free to unlockDoes Ardelyx Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Ardelyx Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Ardelyx Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Ardelyx Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Ardelyx Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Ardelyx Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Ardelyx Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Ardelyx Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Ardelyx Inc disclose its waste policy?
Sign up for free to unlockDoes Ardelyx Inc report according to TCFD requirements?
Sign up for free to unlockDoes Ardelyx Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Ardelyx Inc disclose energy use targets?
Sign up for free to unlockDoes Ardelyx Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Ardelyx Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Ardelyx Inc
These potential risks are based on the size, segment and geographies of the company.
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.